Swedish nationwide study of 58,618 women found 6% experienced treatment-resistant postpartum depression. Risk factors included lower socioeconomic status, smoking, pre-existing health conditions, caesarean or preterm birth.
[read the full story...]
Clozapine is described as the gold standard treatment for schizophrenia but a new cohort study suggests it is associated with an increased risk of infections, particularly in older patients, further solidifying the case for holistic care.
[read the full story...]
A big new study suggests that certain genetic traits—like insomnia risk and neuroticism—may make depression harder to treat, while protective traits include education and cognitive ability.
[read the full story...]
Nuala Murray explores a recent Australian case-control study that looks at the associations between changes in gut microbiota and schizophrenia diagnosis, treatment resistance, and clozapine response.
[read the full story...]
Lorna Staines summarises a recent study on predicting treatment-resistant psychosis, which suggests that future risk prediction efforts should seek to consider routinely collected data.
[read the full story...]
Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.
[read the full story...]
Murtada Alsaif summarises a recent network meta-analysis, which looks at the efficacy, acceptability and tolerability of antipsychotics for treatment-resistant schizophrenia.
[read the full story...]
Andrés Fonseca appraises a new systematic review of interventions for treatment-resistant anxiety in older people, which finds a disconcerting lack of evidence to help him support the many older patients he sees who are affected by anxiety disorders.
[read the full story...]
Treatment-resistant depression (TRD) still represents a challenge to psychiatric practice. Since patients have usually failed at least two antidepressants, drugs originally prescribed for other conditions are often tried as an augmentation (Souery er al., 2006). Amongst them, lithium (a mood-stabiliser used in the treatment of bipolar disorders) as well as atypical antipsychotics (AAPs, indicated for [read the full story…]
Major depression is a serious mental illness that often does not respond to mainstream drug treatment (antidepressants). In addition, there is usually a delay of 2-6 weeks before mood improves significantly. In situations like this, when at least two conventional antidepressants have been tried without success, depression is considered treatment-resistant. While multiple different strategies to [read the full story…]
